

## Special Issue

# Strategies for Combatting Multidrug-Resistant and Extensively Drug-Resistant Bacteria, 2nd Edition

### Message from the Guest Editors

The first volume of the Special Issue “Strategies for Combatting Multidrug-Resistant and Extensively Drug-Resistant Bacteria: Current Challenges and Future Prospects ” was published in October 2023. It is a successful issue with nine published papers, encouraging us to open a second volume on the same topic. As a continuation of the first Special Issue, this second volume will also focus on new strategies, including those that are not only related to novel antimicrobial drugs, but also those related to uncommon drug strategies. The topics of interest include, but are not limited to, the following:

- MDR bacteria;
- EDR bacteria;
- Novel antimicrobial drugs;
- Novel therapeutical approaches against MDR;
- Novel therapeutical approaches against EDR;
- Guidelines;
- Personalized microbiota;
- Bacteriophages;
- Autovaccine therapy;
- Antimicrobial stewardship.

---

### Guest Editors

Dr. Bożena Futoma-Kołodziej  
Dr. Anna Kędziora  
Dr. Adriána Liptáková

---

### Deadline for manuscript submissions

closed (31 July 2025)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/199104](https://mdpi.com/si/199104)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)